TG Therapeutics (NASDAQ:TGTX) Announces Earnings Results

TG Therapeutics (NASDAQ:TGTX) announced its quarterly earnings results on Wednesday. The biopharmaceutical company reported $0.12 EPS for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.11), Briefing.com reports. The company had revenue of $204.92 million during the quarter, compared to analysts’ expectations of $200.33 million. TG Therapeutics had a return on equity of 91.89% and a net margin of 65.95%.TG Therapeutics’s revenue for the quarter was up 69.5% on a year-over-year basis. During the same period last year, the firm earned $0.03 earnings per share.

Here are the key takeaways from TG Therapeutics’ conference call:

• TG Therapeutics reported approximately $195 million in U.S. BRIUMVI net revenue in Q1 (>$200M globally), beat guidance and raised full‑year U.S. guidance to $885M–$900M (global ~$925M) with Q2 targeting ~$220M.
• Commercial momentum shows durable adoption: >25,000 patients prescribed globally, 12 consecutive quarters of sequential growth, record new patient starts, improving persistence versus prior expectations, and leading dynamic CD20 share in private infusion practices.
• Near‑term pipeline catalyst — top‑line data from the Phase III ENHANCE trial (single 600 mg initiation infusion vs. two‑infusion regimen) is expected in the coming weeks, and a positive result could enable a consolidated one‑infusion start and potential launch next year.
• Subcutaneous BRIUMVI program is fully enrolled in Phase III with topline expected year‑end/early next year (Phase I bioavailability data also due soon); management targets a potential 2028 launch and says sub‑Q could materially expand the addressable anti‑CD20 market.
• Capital allocation and balance sheet: the company repurchased ~$100M of stock this quarter (≈6.8M shares total, ~5% of shares outstanding) and has ~$573M in cash/equivalents after extending the Blue Owl facility, while guiding for ~$100M of subcutaneous manufacturing/secondary manufacturer startup costs to be expensed this year.

TG Therapeutics Price Performance

TGTX stock opened at $43.03 on Friday. The company has a debt-to-equity ratio of 0.38, a current ratio of 4.10 and a quick ratio of 3.29. TG Therapeutics has a 1 year low of $25.28 and a 1 year high of $44.00. The firm has a 50-day moving average of $32.72 and a 200 day moving average of $31.60. The company has a market cap of $6.59 billion, a P/E ratio of 15.05 and a beta of 1.68.

Wall Street Analyst Weigh In

TGTX has been the topic of several analyst reports. Wall Street Zen downgraded shares of TG Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, February 14th. Weiss Ratings raised shares of TG Therapeutics from a “hold (c)” rating to a “hold (c+)” rating in a research note on Friday, May 1st. Zacks Research cut TG Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Friday, May 1st. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of TG Therapeutics in a research report on Wednesday, January 14th. Finally, The Goldman Sachs Group increased their price objective on TG Therapeutics from $37.00 to $39.00 and gave the stock a “neutral” rating in a report on Thursday, January 15th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $52.50.

Key Stories Impacting TG Therapeutics

Here are the key news stories impacting TG Therapeutics this week:

• Positive Sentiment: HC Wainwright materially raised EPS estimates across 2026–2030 (examples: FY2026 to $1.30 from $0.94; FY2027 to $2.45; FY2030 to $4.88) and reiterated a Buy rating with a $70 price target — a clear analyst catalyst for upside expectations. (no direct link)
• Positive Sentiment: Company reported strong Briumvi sales and raised its 2026 revenue guidance, which investors are viewing as validation of commercial momentum and top-line durability. TG Therapeutics Reports First Quarter 2026 Financial Results and Raises BRIUMVI Revenue Guidance
• Positive Sentiment: Retail and momentum flows pushed the stock to a fresh 52-week high despite the EPS miss, indicating strong market appetite for the story and follow-through buying. TGTX stock hits fresh 52-week high – here’s why retail is bullish despite Q1 earnings miss
• Neutral Sentiment: Full Q1 call/transcript is available for investors who want detail on guidance drivers, channel inventory, and commercial cadence — useful for due diligence but not an immediate directional driver. TG Therapeutics (TGTX) Q1 2026 Earnings Transcript
• Negative Sentiment: Q1 EPS missed consensus (reported ~$0.17 vs. ~0.23 expected), which is a short-term negative on profitability metrics; however, management’s revenue/guide beat and upgraded analyst forecasts have largely offset the reaction. TGTX Q1 Earnings Miss, Sales Rise Y/Y, Stock Up on Raised 2026 View

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. State Street Corp lifted its stake in shares of TG Therapeutics by 4.7% in the 4th quarter. State Street Corp now owns 8,479,999 shares of the biopharmaceutical company’s stock valued at $252,789,000 after purchasing an additional 379,380 shares during the period. Goldman Sachs Group Inc. lifted its position in TG Therapeutics by 35.0% during the fourth quarter. Goldman Sachs Group Inc. now owns 2,051,132 shares of the biopharmaceutical company’s stock valued at $61,144,000 after buying an additional 531,759 shares during the period. Invesco Ltd. grew its position in shares of TG Therapeutics by 47.1% in the 4th quarter. Invesco Ltd. now owns 1,609,815 shares of the biopharmaceutical company’s stock worth $47,989,000 after buying an additional 515,481 shares during the period. Man Group plc increased its stake in shares of TG Therapeutics by 621.5% in the 3rd quarter. Man Group plc now owns 1,008,462 shares of the biopharmaceutical company’s stock worth $36,431,000 after acquiring an additional 868,697 shares in the last quarter. Finally, Nuveen LLC lifted its position in TG Therapeutics by 34.1% during the 4th quarter. Nuveen LLC now owns 953,206 shares of the biopharmaceutical company’s stock valued at $28,415,000 after acquiring an additional 242,434 shares during the period. Hedge funds and other institutional investors own 58.58% of the company’s stock.

TG Therapeutics Company Profile

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.